



General Assembly

January Session, 2025

Raised Bill No. 6771

LCO No. 3669



Referred to Committee on AGING

Introduced by:
(AGE)

***AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR
BIOMARKER TESTING.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2026*) (a) As used in this section:

2 (1) "Biomarker" means a characteristic, including, but not limited to,
3 a gene mutation or protein expression that can be objectively measured
4 and evaluated as an indicator of normal biological processes, pathogenic
5 processes or pharmacologic responses to a specific therapeutic
6 intervention for a disease or condition.

7 (2) "Biomarker testing" means the analysis of a patient's tissue, blood
8 or other biospecimen for the presence of a biomarker, including, but not
9 limited to, tests for a single substance, tests for multiple substances,
10 diseases or conditions and whole genome sequencing.

11 (b) Each individual health insurance policy providing coverage of the
12 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469
13 of the general statutes delivered, issued for delivery, renewed, amended
14 or continued in this state on or after January 1, 2026, shall provide

15 coverage for biomarker testing for the purpose of diagnosis, treatment,
16 appropriate management or ongoing monitoring of an insured's disease
17 or condition.

18 Sec. 2. (NEW) (*Effective January 1, 2026*) (a) As used in this section:

19 (1) "Biomarker" means a characteristic, including, but not limited to,
20 a gene mutation or protein expression that can be objectively measured
21 and evaluated as an indicator of normal biological processes, pathogenic
22 processes or pharmacologic responses to a specific therapeutic
23 intervention for a disease or condition.

24 (2) "Biomarker testing" means the analysis of a patient's tissue, blood
25 or other biospecimen for the presence of a biomarker, including, but not
26 limited to, tests for a single substance, tests for multiple substances,
27 diseases or conditions and whole genome sequencing.

28 (b) Each group health insurance policy providing coverage of the
29 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469
30 of the general statutes delivered, issued for delivery, renewed, amended
31 or continued in this state on or after January 1, 2026, shall provide
32 coverage for biomarker testing for the purpose of diagnosis, treatment,
33 appropriate management or ongoing monitoring of an insured's disease
34 or condition.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2026</i>	New section
Sec. 2	<i>January 1, 2026</i>	New section

Statement of Purpose:

To require health insurance coverage for biomarker testing.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]

